LifeSci Capital analyst Charles Zhu maintained a Buy rating on Protara Therapeutics today and set a price target of $26.00. The company’s shares...
LifeSci Capital analyst Charles Zhu maintained a Buy rating on Protara Therapeutics today and set a price target of $26.00. The company’s shares...